clinical trial · NCT02847624
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Otsuka Pharmaceutical Co., Ltd.·—·completed·n = 1,802
Polycystic Kidney, Autosomal Dominanttolvaptan
brief summary
The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.
started
Mar 24, 2014
primary completion
Sep 20, 2022
completion
Sep 20, 2022
last updated
Dec 10, 2025
official title
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol